CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer

CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer

Abstract Background The cyclin-dependent kinase 7 (CDK7) subunit of TFIIH regulates RNA polymerase-II-based transcription and promotes tumor progression. However, the mechanisms involved in CDK7-mediated immune evasion are unclear in non-small cell lung cancer (NSCLC). Methods RNA silencing and phar...

Full description

Bibliographic Details
Main Authors: Jian Wang, Ruiguang Zhang, Zhenyu Lin, Sheng Zhang, Yaobing Chen, Jing Tang, Jiaxin Hong, Xiaoshu Zhou, Yan Zong, Yingzhuo Xu, Rui Meng, Shuangbing Xu, Li Liu, Tao Zhang, Kunyu Yang, Xiaorong Dong, Gang Wu
Format: Article
Language:English
Published: BMC 2020-07-01
Series:Journal of Hematology & Oncology
Subjects:
CDK7
p38α
MYC
PD-L1
Non-small cell lung cancer
Online Access:http://link.springer.com/article/10.1186/s13045-020-00926-x

Internet

http://link.springer.com/article/10.1186/s13045-020-00926-x

Similar Items